Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.

ABSTRACT:

Purpose

Neoadjuvant chemoradiation is an alternative to the surgery-first approach for resectable pancreatic cancer (PDA) and represents the standard of care for borderline resectable (BLR).

Materials and methods

All patients with resectable and BLR PDA treated with neoadjuvant chemoradiation using IMRT between 1/2009 and 11/2011 were reviewed. Patients were treated to a customized CTV which included the primary mass and regional vessels.

Results

Neoadjuvant chemoradiation was completed in 69 patients (39 BLR and 30 resectable). Induction chemotherapy was used in 32 (82%) of the 39 patients with BLR disease prior to chemoXRT. All resectable patients were treated with chemoXRT alone. Following neoadjuvant treatment, 48 (70%) of the 69 patients underwent successful panc

SUBMITTER: Kharofa J 

PROVIDER: S-EPMC4530020 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature